DA
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Resilience in Alzheimer's disease: Impact of operationalization and methodological choices | Alzheimer's & dementia |  | 2025 | 106 | 85 | ||
| Alterations in gamma frequency oscillations correlate with cortical tau deposition in Alzheimer’s disease | Neurobiology of aging | | 2024 | 118 | 126 | ||
| Association Between Years of Education and Amyloid Burden in Patients With Subjective Cognitive Decline, MCI, and Alzheimer Disease | Neurology | | 2024 | 96 | 71 | ||
| Plasma biomarkers for Alzheimer's disease: a field-test in a memory clinic | Journal of neurology, neurosurgery and psychiatry | | 2023 | 260 | 90 | ||
| Recruitment of pre-dementia participants : main enrollment barriers in a longitudinal amyloid-PET study | Alzheimer's research & therapy | | 2023 | 72 | 18 | ||
| Description of a European memory clinic cohort undergoing amyloid-PET: The AMYPAD Diagnostic and Patient Management Study | Alzheimer's & dementia | | 2023 | 145 | 74 | ||
| Analysis of psychological symptoms following disclosure of amyloid-positron emission tomography imaging results to adults with subjective cognitive decline | JAMA network open | | 2023 | 89 | 63 | ||
| Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients : The AMYPAD-DPMS Randomized Clinical Trial | JAMA neurology | | 2023 | 68 | 46 | ||
| Dementia prevention in memory clinics : recommendations from the european task force for brain health services | The Lancet regional health. Europe | | 2023 | 114 | 128 | ||
| The probabilistic model of Alzheimer disease: the amyloid hypothesis revised | Nature reviews. Neuroscience |  | 2022 | 163 | 1 | ||
| Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe | Alzheimer's & dementia | | 2022 | 351 | 228 | ||
| The amyloid imaging for the prevention of Alzheimer's disease consortium : A European collaboration with global impact | Frontiers in neurology | | 2022 | 69 | 14 | ||
| The Clinical Use of Alzheimer's Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer's Disease Consortium Survey | Journal of Alzheimer's disease | | 2022 | 91 | 59 | ||
| Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study | Magnetic resonance imaging | | 2021 | 106 | 0 | ||
| Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services-part 4 of 6 | Alzheimer's research & therapy | | 2021 | 183 | 198 | ||
| Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison | European Journal of Nuclear Medicine and Molecular Imaging | | 2021 | 341 | 162 | ||
| Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): rationale and study design | Alzheimer's Research and Therapy | | 2021 | 436 | 282 | ||
| Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services—part 1 of 6 | Alzheimer's research & therapy | | 2021 | 219 | 213 | ||
| Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services — part 2 of 6 | Alzheimer's research & therapy | | 2021 | 159 | 152 | ||
| Protocols for cognitive enhancement. a user manual for brain health services — part 5 of 6 | Alzheimer's research & therapy | | 2021 | 156 | 118 | ||
| Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives | European journal of nuclear medicine and molecular imaging | | 2021 | 219 | 88 | ||
| Societal and equity challenges for Brain Health Services. A user manual for Brain Health Services — part 6 of 6 | Alzheimer's research & therapy | | 2021 | 126 | 77 | ||
| Dementia risk communication. A user manual for Brain Health Services — part 3 of 6 | Alzheimer's research & therapy | | 2021 | 133 | 130 | ||
| Multitracer model for staging cortical amyloid deposition using PET imaging | Neurology | | 2020 | 10 | 11 | ||
| Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease | European Journal of Nuclear Medicine and Molecular Imaging | | 2020 | 409 | 6 | ||
| Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study | Alzheimer's & Dementia | | 2020 | 496 | 163 | ||
| Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies | Alzheimer's & Dementia | | 2020 | 261 | 2 | ||
| Applying the ATN scheme in a memory clinic population: The ABIDE project | Neurology | | 2019 | 416 | 1 | ||
| Medial temporal lobe atrophy and posterior atrophy scales normative values | NeuroImage: Clinical | | 2019 | 497 | 239 | ||
| Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset | Journal of Neurology | | 2019 | 343 | 332 | ||
| Is a large-scale screening for Alzheimer's disease possible? yes, in a few years | The Journal of Prevention of Alzheimer's Disease | | 2019 | 304 | 7 | ||
| Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia | European Journal of Nuclear Medicine and Molecular Imaging | | 2018 | 469 | 0 | ||
| Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease | European Journal of Nuclear Medicine and Molecular Imaging | | 2018 | 453 | 0 | ||
| Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia | European Journal of Nuclear Medicine and Molecular Imaging | | 2018 | 434 | 0 | ||
| Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders | European Journal of Nuclear Medicine and Molecular Imaging | | 2018 | 359 | 0 | ||
| Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease with Transcranial Magnetic Stimulation | Journal of Alzheimer's Disease | | 2018 | 392 | 0 | ||
| Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia | European Journal of Nuclear Medicine and Molecular Imaging | | 2018 | 499 | 192 | ||
| Quantitative appraisal of the Amyloid Imaging Taskforce appropriate use criteria for amyloid-PET | Alzheimer's & Dementia | | 2018 | 447 | 0 | ||
| Clinical utility of FDG-PET for the clinical diagnosis in MCI | European Journal of Nuclear Medicine and Molecular Imaging | | 2018 | 449 | 0 | ||
| Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease | European Journal of Nuclear Medicine and Molecular Imaging | | 2018 | 446 | 0 | ||
| Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia | European Journal of Nuclear Medicine and Molecular Imaging | | 2018 | 431 | 199 | ||
| AMYPAD Diagnostic and Patient Management Study: Rationale and design | Alzheimer's & Dementia | | 2018 | 467 | 288 | ||
| Do Beliefs about the Pathogenetic Role of Amyloid Affect the Interpretation of Amyloid PET in the Clinic | Neurodegenerative Diseases | | 2016 | 418 | 1 | ||
| Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study | JAMA neurology | | 2016 | 479 | 2 | ||
| Brain atrophy in Alzheimer's Disease and aging | Ageing research reviews | | 2016 | 736 | 7 |
